EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/14/2025
Back to search
Official data from USPTO
INPEFA. SOTAGLIFLOZIN TABLETS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/19/2025
Trademark type
Combined
Nice classes
5
Filing date
10/28/2022
Registration date
08/15/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/15/2023
Last transaction
04/19/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/18/2023
First use in commerce
05/18/2023
Drawing code
5
Owner type
03
Owner location
The Woodlands, TX
Examiner
VOHRA, SANJEEV
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of stlylized phrase "inpefa. sotagliflozin tablets".
Holders and representatives
Holders
Lexicon Pharmaceuticals, Inc.
Representatives
Tania Shapiro-Barr Viksnins Harris Padys Malen LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment or prevention of heart failure
Publications
History of USPTO decisions and trademark events.
30 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/14/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/14/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/15/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/15/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/11/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/10/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/17/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/16/2023
EX1G
SOU EXTENSION 1 GRANTED
06/16/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/16/2023
IUAF
USE AMENDMENT FILED
06/08/2023
EXT1
SOU EXTENSION 1 FILED
06/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
06/08/2023
EISU
TEAS STATEMENT OF USE RECEIVED
06/08/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/24/2023
PUBO
PUBLISHED FOR OPPOSITION
01/24/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/21/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/06/2022
GNRT
NON-FINAL ACTION E-MAILED
12/06/2022
CNRT
NON-FINAL ACTION WRITTEN
12/06/2022
DOCK
ASSIGNED TO EXAMINER
11/29/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/15/2022
NWAP
NEW APPLICATION ENTERED
11/01/2022
Continuous trademark protection
Get notified about every new filing that threatens INPEFA. SOTAGLIFLOZIN TABLETS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.